Can adding radiation to osimertinib keep lung cancer in check?
NCT ID NCT05089916
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether it is safe and effective to continue the targeted therapy osimertinib while also giving radiation to areas where lung cancer has started to grow again. The study includes 42 adults with EGFR-positive non-small cell lung cancer who are already on osimertinib. Researchers will monitor side effects, cancer progression, and quality of life during and after the combined treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Osimertinib (Tagrisso) and radiotherapy
What this could lead to
If successful, this could show that combining osimertinib with targeted radiation is safe and helps control cancer growth longer in patients with limited progression.
What could go wrong
This is a small, early-phase study with only 42 participants, so results may not apply broadly. There is a risk of serious side effects like lung inflammation or heart problems from the combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
LMU Klinikum der Universität München
München, 80336, Germany